Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital
June 27, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and...
Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference
June 11, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., June 11, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019...
Antares Pharma to Present at the Jefferies 2019 Healthcare Conference
May 30, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019...
Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference
May 16, 2019 17:00 ET
|
Antares Pharma, Inc.
EWING, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B....
Antares Pharma Reports First Quarter 2019 Operating and Financial Results
May 02, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019. The...
Antares Pharma to Report First Quarter 2019 Financial and Operating Results
April 18, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., April 18, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the...
Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate
March 28, 2019 07:30 ET
|
Antares Pharma, Inc.
EWING, N.J., March 28, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate (“MTX”) for...
Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference
March 06, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company...
Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella
March 04, 2019 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat being...
Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
February 28, 2019 07:00 ET
|
Antares Pharma, Inc.
Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, N.J., Feb. 28, 2019 (GLOBE...